9 Sources of Evidence
The following documentation and opinion was made available to the committee:
a. Assessment Report prepared by the Department of Public Health and Epidemiology, University of Birmingham (Fludarabine as second line therapy for B-Cell chronic lymphocytic leukaemia, January 2001)
Assessment Report Annexe prepared by the Department of Public Health and Epidemiology, University of Birmingham (Fludarabine as second line therapy for B-Cell chronic lymphocytic leukaemia: Effectiveness Annexe, May 2001)
Assessment Report Cost- Effectiveness Annexe prepared by Dr A J Fischer, NICE Appraisals Team, May 2001
b. Manufacturer/Sponsor submissions:
-
Schering Health Care Ltd
c. Professional/Specialist Group, Patient/Carer Group and Trade Association submissions:
-
British National Lymphoma Investigation and UK CCCR
-
British Committee for Standards in Haematology (BCSH)
-
CancerBACUP
-
Lymphoma Association
-
Macmillan Cancer Relief
-
Royal College of Pathologists
d. External expert and patient advocate submissions:
-
Dr Andrew MacMillan, Oncologist, Mount Vernon Hospital
-
Dr Peter Hoskin, Consultant Clinical Oncologist, Mount Vernon Hospital
-
Dr Tracey Murray, Lecturer/Practitioner, St George's Healthcare NHS Trust
-
Catriona Moore, Policy Officer, CancerBACUP
-
Judith Brodie, Head of Cancer Support Services, CancerBACUP
-
Catriona Gilmour Hamilton, Assistant Head of Information Services, The Lymphoma Association